We are pioneering an entirely new class of medicines designed to go beyond the limits of today’s treatments for cancer
Learn more >>We are pioneering an entirely new class of medicines designed to go beyond the limits of today’s treatments for cancer
Learn more >>We are deeply motivated to improve the options available to people with cancer.
Hear what drives us to go the extra mile.
I’ve known this company from the beginning, and I still find that doing something that matters inspires me every day.
We are in urgent need of new medicines for all those with cancer — including many we know personally. This thought keeps me motivated to give my best.
I am inspired by how an idea within a university lab has been transformed into a publicly-listed company with the opportunity to make a meaningful impact in patients’ lives.
I know that with our team at MP we can make a difference for patients — and if it is only for one it’s worth it.
My favorite part about Molecular Partners is the passion for developing innovative therapeutic options and the strong dedication towards a common goal: helping patients in need.
I joined Molecular Partners to find an interesting job – and I stayed for the passion to build something meaningful!
I’m inspired on a daily basis by Molecular Partners’ high-quality science, my driven colleagues, and our potential impact on the lives of cancer patients.
My favorite part about Molecular Partners is working together within a team of specialists and seeing the direct impact of my daily work on the development of drugs.
Our team — and in the end our patients as well — benefit from our collaborative, inclusive and smart ways of working together.
The Molecular Partners team is unique because we share a common vision and combine our diverse experiences and skill sets to achieve our goals.
Molecular Partners continues to monitor the situation surrounding the COVID-19 pandemic and its potential impact on patients, our team, our partners and our business.
Presently, we can report no major disruptions. We are complying with all local and federal instructions as it relates to the safety of our employees, patients, and citizens. All employees who can are working remotely. Our laboratories remain operational and those employees who are in the office are practicing physical distancing and undertaking all appropriate safety measures.
We have initiated a therapeutic program leveraging the DARPin® platform to create the first trispecific antiviral drug. We are working to rapidly advance preclinical testing. Learn more here.
We recognize that this is a fluid situation and we continue to evaluate what, if any, potential impacts may occur, and we will update accordingly. We look forward to resuming normal operations.
Best wishes,
Molecular Partners
April 20, 2020
